-+ 0.00%
-+ 0.00%
-+ 0.00%

CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING

Reuters·05/15/2026 20:05:00

Please log in to view news